NeuroSense Therapeutics Ltd. Increase Decrease In Cash And Cash Equivalents
NeuroSense Therapeutics Ltd. (NRSN) reported Increase Decrease In Cash And Cash Equivalents of -$903.00 thousand for the 12-month period ending 2023-12-31, per its 20-F filed 2024-04-04.
Discontinued › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseInCashAndCashEquivalents · last filed 2024-04-04
| Period end | Increase Decrease In Cash And Cash Equivalents 6 month | Increase Decrease In Cash And Cash Equivalents 12 month |
|---|---|---|
| 2023-12-31 | -$903.00K 20-F · filed 2024-04-04 | |
| 2023-06-30 | $3.55M 6-K · filed 2023-08-16 | |
| 2022-12-31 | -$7.52M 20-F · filed 2024-04-04 | |
| 2022-06-30 | -$6.71M 6-K · filed 2023-08-16 | |
| 2021-12-31 | $10.36M 20-F · filed 2024-04-04 | |
| 2021-06-30 | $295.00K 6-K/A · filed 2023-01-19 | |
| 2020-12-31 | -$196.00K 20-F · filed 2023-03-22 | |
| 2019-12-31 | $809.00K 20-F · filed 2022-04-14 |